In vitro Activity of Quinupristin/ Dalfopristin, RP59500, against Gram-Positive Clinical Isolates

Chemotherapy ◽  
1997 ◽  
Vol 43 (2) ◽  
pp. 94-99 ◽  
Author(s):  
Hussain Qadri ◽  
Y. Ueno ◽  
Abu Mostafa ◽  
Majid Halim
2010 ◽  
Vol 25 (1) ◽  
Author(s):  
Elisabetta Maioli ◽  
Erika Coppo ◽  
Ramona Barbieri ◽  
Elisabetta Canepa ◽  
Laura Gualco ◽  
...  

2008 ◽  
Vol 62 (1) ◽  
pp. 116-121 ◽  
Author(s):  
D. C. Draghi ◽  
B. M. Benton ◽  
K. M. Krause ◽  
C. Thornsberry ◽  
C. Pillar ◽  
...  

Chemotherapy ◽  
1997 ◽  
Vol 43 (6) ◽  
pp. 393-399 ◽  
Author(s):  
Giovanni Bonfiglio ◽  
Giuseppa Maccarone ◽  
Maria Lina Mezzatesta ◽  
Angela Privitera ◽  
Vincenzo Carciotto ◽  
...  

1999 ◽  
Vol 33 (4) ◽  
pp. 299-303 ◽  
Author(s):  
Shan-Chwen Chang ◽  
Chi-Tai Fang ◽  
Po-Ren Hsueh ◽  
Kwen-Tay Luh ◽  
Wei-Chuan Hsieh

1998 ◽  
Vol 42 (9) ◽  
pp. 2452-2455 ◽  
Author(s):  
Fernando García-Garrote ◽  
Emilia Cercenado ◽  
Luis Alcalá ◽  
Emilio Bouza

ABSTRACT The in vitro activity of LY333328 was compared with those of vancomycin and teicoplanin against 425 gram-positive clinical isolates, including a variety of multiply resistant strains. LY333328 at ≤4 μg/ml inhibited all microorganisms tested, including methicillin- and teicoplanin-resistant staphylococci, glycopeptide-resistant enterococci, penicillin- and multiply resistant pneumococci, and viridans and beta-hemolytic streptococci.


2016 ◽  
Vol 3 (suppl_1) ◽  
Author(s):  
Rodrigo E. Mendes ◽  
Robert K. Flamm ◽  
Michael Pfaller ◽  
Mariana Castanheira ◽  
Helio S. Sader

2007 ◽  
Vol 60 (9) ◽  
pp. 572-576 ◽  
Author(s):  
Christopher K Murphy ◽  
Elena Karginova ◽  
Dan Sahm ◽  
David M Rothstein

Sign in / Sign up

Export Citation Format

Share Document